Patents Examined by Jeremy C Flinders
  • Patent number: 11326160
    Abstract: This disclosure provides, among other things, a method for making a cDNA library. In some embodiments the method may comprise reverse transcribing mRNA to produce DNA:mRNA hybrids, treating the DNA:mRNA hybrids with RNAseH to produce mRNA fragments, and reverse transcribing the mRNA fragments.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: May 10, 2022
    Assignee: BIOO SCIENTIFIC CORPORATION
    Inventors: Kevin Allen, Adam Morris
  • Patent number: 11300574
    Abstract: Disclosed herein are isolated compositions including at least 2 of mutant peptides selected from the group consisting of SEQ ID NOS: 1-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 2 or more genes. Also disclosed are methods for personalized treatment of breast cancer involving creating a peptide array of mutant peptides comprising the mutations in protein-encoding regions of the high-frequency cancer genes or the exome in a subject and screening the peptide array with a biological sample from the subject to detect antibodies in the biological sample that bind to the array, to detect antigenic targets for therapy in treating the subject.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 12, 2022
    Assignee: UNIVERSITY OF CONNECTICUT
    Inventors: David Han, Veneta Qendro
  • Patent number: 11287417
    Abstract: Methods and systems for evaluating heath/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 29, 2022
    Assignee: IXCELA, INC.
    Inventors: Wayne R. Matson, Samantha A. Matson, Erika N. Ebbel-Angle, Srikant Sarangi
  • Patent number: 11287418
    Abstract: Methods and systems for evaluating health/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's health based on the metabolite levels measured.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 29, 2022
    Assignee: IXCELA, INC.
    Inventors: Wayne R. Matson, Samantha A. Matson, Erika N. Ebbel-Angle, Srikant Sarangi
  • Patent number: 11287420
    Abstract: Methods and systems for evaluating heath/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 29, 2022
    Assignee: IXCELA, INC.
    Inventors: Wayne R. Matson, Samantha A. Matson, Erika N. Ebbel-Angle, Srikant Sarangi
  • Patent number: 11287419
    Abstract: Methods and systems for evaluating health/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 29, 2022
    Assignee: IXCELA, INC.
    Inventors: Wayne R. Matson, Samantha A. Matson, Erika N. Ebbel-Angle, Srikant Sarangi
  • Patent number: 11279971
    Abstract: The present invention includes an in-situ method, comprising a) determining a molecule selected from the group consisting of cell surface molecules and extracellular matrix molecules in a two- or three-dimensional cell culture system comprising living cells and cell culture medium, comprising the steps of i) providing an analyte probe consisting of a detection element, which binds the molecule, and one or more identification elements; ii) binding of the analyte probe to the molecule in the cell culture system, wherein the growth ability of the contained living cells is not substantially impaired by this step; iii) optionally removing unbound analyte probes; iv) releasing the analyte probe; v) transferring the analyte probe into a container which differs from the cell culture system; vi) detecting the identification element(s); and b) continuing the cell cultivation in the cell culture system.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: March 22, 2022
    Assignee: LIFETAQ-ANALYTICS GMBH
    Inventors: Manfred Taschner, Volker Lorber
  • Patent number: 11275030
    Abstract: This disclosure provides methods and devices for the label-free detection of target molecules of interest. The principles of the disclosure are particularly applicable to the detection of biological molecules (e.g., DNA, RNA, and protein) using standard SiO2-based microarray technology.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 15, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: M. Selim Unlu, David A. Bergstein, Michael F. Ruane, Bennett B. Goldberg
  • Patent number: 11274295
    Abstract: The invention provides methods for generating pools of variants of DNA templates, and methods of using pools of variants to identify sequences involved in conferring sensitivity or resistance to environmental factors.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: March 15, 2022
    Assignee: THE BROAD INSTITUTE, INC.
    Inventors: Tarjei Mikkelsen, Alexandre Melnikov
  • Patent number: 11260363
    Abstract: The present invention provides a formulation to link protein to a solid support that comprises one or more proteins, Oligo-dT and one or more non-volatile, water-soluble protein solvents, solutes or combination thereof in an aqueous solution. Further provided is a method of attaching a protein to a surface of a substrate. The formulations provided herein are contacted onto the substrate surface, printed thereon and air dried. The substrate surface is irradiated with UV light to induce thymidine photochemical crosslinking via the thymidine moieties of the Oligo-dT.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: March 1, 2022
    Assignee: PURE TRANSPLANT SOLUTIONS L.L.C.
    Inventor: Michael E. Hogan
  • Patent number: 11248226
    Abstract: A method for producing a ribosome display complex includes obtaining a ribosome complex including an unmodified polypeptide chain, an mRNA molecule and a ribosome by initiating translation of the mRNA molecule in a cell-free peptide synthesis system including the ribosome, and modifying the unmodified polypeptide chain by reacting a side chain reactive functional group in the unmodified polypeptide chain with a modifying reagent to produce a ribosome display complex including a modified polypeptide chain, the mRNA molecule and the ribosome. The unmodified polypeptide chain includes at least one reactive amino acid residue selected from the group consisting of a cysteine residue, a lysine residue, a histidine residue and a tryptophan residue. The at least one reactive amino acid residue includes the side chain reactive functional group, and the mRNA molecule includes a base sequence encoding an amino acid sequence of the polypeptide chain.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: February 15, 2022
    Assignee: KANEKA CORPORATION
    Inventors: Hiroshi Kita, Toshihiro Shikakura, Hirofumi Maeda, Keishi Takatsu
  • Patent number: 11248223
    Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: February 15, 2022
    Assignee: CureVac AG
    Inventors: Benyamin Yazdan Panah, Aniela Wochner, Tilmann Roos, Andreas Funkner, Martin Kunze
  • Patent number: 11237168
    Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 1, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: J. Paul Taylor, Peiguo Yang, Wenwei Lin, Taosheng Chen
  • Patent number: 11221340
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: January 11, 2022
    Assignee: SomaLogic, Inc.
    Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Patent number: 11221341
    Abstract: Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A (SEQ ID NO.1) is determined.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: January 11, 2022
    Assignees: Commissariat a 1'Energie Atomique et aux Energies Alternatives, Centre Hospitalier Universitaire, Universite Grenoble Alpes, Institut National de la Sante et de la Recherche Medicale, Universite Paris Sud
    Inventors: Virginie Brun, Jérôme Garin, Christophe Bruley, Jamila Faivre, Jean-Pierre Zarski, Vincent Leroy
  • Patent number: 11209412
    Abstract: Provided are a microfluidic biosensors that are suitable for continuously monitoring toxin levels in water supplies.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 28, 2021
    Assignee: The Regents of the University of California
    Inventors: Jeff Hasty, Leo Alexander Baumgart, Scott Cookson, Michael Ferry, Garrett Graham, Ramon Huerta, Ryan Johnson, Lev Tsimring
  • Patent number: 11187703
    Abstract: Disclosed herein is a method of determining whether a subject has or is at risk of developing a cancer. The method comprises, obtaining a sample from the subject; determining the levels of at least two target polypeptides, which are selected from the group consisting of, ANXA2, HSPA5, KNG1 and MMP1; and assessing whether the subject has or is at risk of developing the cancer based on the levels of target polypeptides. The present method provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma, and accordingly, the subject in need thereof could receive a suitable therapeutic regimen in time.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 30, 2021
    Assignee: S&T BIOMED CO., LTD.
    Inventors: Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung-Chin Hsiao, Yu-Sun Chang, Lai-Chu See, Kai-Ping Chang
  • Patent number: 11180752
    Abstract: Systems, methods, and compositions provided herein relate to preparation of beads encapsulating long DNA fragments for high-throughput spatial indexing. Some embodiments include preparation of nucleic acid libraries within the bead, wherein the bead includes pores that allow diffusion of reagents while retaining genetic material.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: November 23, 2021
    Assignee: ILLUMINA, INC.
    Inventors: Yir-Shyuan Wu, Filiz Gorpe-Yasar, Tarun Kumar Khurana, Victoria Popic, Erich B. Jaeger, Mostafa Ronaghi
  • Patent number: 11180382
    Abstract: A process for removing lead from a liquid is provided. The liquid is brought into contact with PbrD proteins having an amino acid sequence which has at least 80% identity to SEQ ID NO: 2, and these proteins bind to lead ions present in the liquid, thus removing the lead ions from the liquid. The bound lead ions are subsequently recovered, such as in the form of an insoluble salt or compound or by cation exchange chromatography, and can then be recycled. The PbrD protein can be immobilized before being brought into contact with the liquid. The proteins are typically immobilized in a matrix of nanoparticles. The PbrD proteins can be recombinantly expressed, such as in a bacterial system (e.g. E. coli) or a yeast expression system.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 23, 2021
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Kulsum Kondiah, Paul John Franklyn, Vidya Keshav
  • Patent number: 11168355
    Abstract: Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: November 9, 2021
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Georg Seelig, Richard Muscat, Alexander B. Rosenberg